Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schaich

Showing results (411-420 of 421) with videos related to

Pageof 43
Sort By:
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Journal of Hematology & Oncology|May 13, 2022
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Pageof 43

Showing results (411-420 of 421) with videos related to

Sort By:
Pageof 43
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Journal of Hematology & Oncology|May 13, 2022
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Pageof 43